Payment overview · 2025
General Payments
$122.03
6 reported records · 4 companies
Healthcare provider profile · identity verified
Anne E. Kristensen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1861499733
Verified facts
What the public records show
CMS Open Payments records show Anne E. Kristensen, M.D. received $122.03 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.27 | 38.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 36.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.15 | 13.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.61 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.03 | 5 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.27 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.27 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
150 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 879 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 223 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 715 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 703 | 184 |
| Losartan Potassium | Losartan Potassium | 581 | 176 |
| Alprazolam | Alprazolam | 520 | 103 |
| Lisinopril | Lisinopril | 350 | 98 |
| Omeprazole | Omeprazole | 333 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 92 |
| Gabapentin | Gabapentin | 302 | 87 |
| Tramadol Hcl | Tramadol Hcl | 299 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 87 |
| Metformin Hcl | Metformin Hcl | 276 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 271 | 50 |
| Simvastatin | Simvastatin | 265 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 228 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 71 |
| Trazodone Hcl | Trazodone Hcl | 212 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 69 |
| Lorazepam | Lorazepam | 186 | 32 |
| Eliquis | Apixaban | 183 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 181 | 32 |
| Temazepam | Temazepam | 177 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 50 |
| Glimepiride | Glimepiride | 171 | 49 |
| Carvedilol | Carvedilol | 164 | 46 |
| Potassium Chloride | Potassium Chloride | 162 | 46 |
| Azithromycin | Azithromycin | 159 | 105 |
| Mounjaro | Tirzepatide | 150 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 150 | 47 |
| Alendronate Sodium | Alendronate Sodium | 141 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 42 |
| Ibuprofen | Ibuprofen | 137 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 38 |
| Ozempic | Semaglutide | 126 | 24 |
| Famotidine | Famotidine | 124 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 46 |
| Furosemide | Furosemide | 120 | 41 |
| Diazepam | Diazepam | 118 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 117 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 32 |
| Methylprednisolone | Methylprednisolone | 102 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 102 | 14 |
| Prednisone | Prednisone | 101 | 55 |
| Sertraline Hcl | Sertraline Hcl | 100 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 34 |
| Atenolol | Atenolol | 98 | 26 |
| Pregabalin | Pregabalin | 95 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 35 |
| Montelukast Sodium | Montelukast Sodium | 94 | 31 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 89 | 28 |
| Allopurinol | Allopurinol | 86 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 61 |
| Irbesartan | Irbesartan | 85 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 59 |
| Naproxen | Naproxen | 81 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 24 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 75 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 18 |
| Clonazepam | Clonazepam | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 15 |
| Estradiol | Estradiol | 69 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 21 |
| Metformin Hcl Er | Metformin Hcl | 68 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 14 |
| Meloxicam | Meloxicam | 67 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 17 |
| Donepezil Hcl | Donepezil Hcl | 62 | 20 |
| Jardiance | Empagliflozin | 61 | 22 |
| Celecoxib | Celecoxib | 58 | 17 |
| Lovastatin | Lovastatin | 57 | 16 |
| Finasteride | Finasteride | 56 | 18 |
| Amoxicillin | Amoxicillin | 55 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 15 |
| Xarelto | Rivaroxaban | 53 | 14 |
| Baclofen | Baclofen | 52 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Levofloxacin | Levofloxacin | 50 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | 16 |
| Cephalexin | Cephalexin | 48 | 29 |
| Valsartan | Valsartan | 48 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 14 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Hydrocortisone | Hydrocortisone | 45 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 13 |
| Acyclovir | Acyclovir | 44 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 15 |
| Spironolactone | Spironolactone | 37 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 13 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 15 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 14 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ibu | Ibuprofen | 32 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 18 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Prolia | Denosumab | 19 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.03 · 6 records | Amgen Inc. | OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error